2022ReviewDrug Delivery
Lei W, Yang C, Wu Y, Ru G, He X, Tong X, Wang S.
Conventional chemotherapy suffers from poor targeting and severe side effects, while synthetic nanocarriers are often cleared by the immune system and lack precise tumor targeting. Cell membrane-coated nanocarriers (CMCNs) offer a biomimetic strategy to improve biocompatibility, immune evasion, circulation time, and homotypic tumor targeting. RBC membrane-coated PLGA nanocarriers improved blood retention to 72 hours vs 15.8 hours for typical PEGylated stealth nanocarriers. - Neutrophil membrane-coated nanocarriers showed 2–3-fold higher accumulation in.
Read the article →Advanced Science.2022ReviewDrug Delivery
De R, Mahata Mk, Kim K-T
Drug carriers are as important as drugs themselves, but clinical translation of polymeric nanocarriers (PNCs) remains limited by incomplete understanding of how carrier architecture and physicochemical properties affect loading, circulation, targeting, and release. The review addresses this gap by systematically linking structural varieties of PNCs and their physicochemical properties to drug delivery profiles, and by highlighting. Representative quantitative findings highlighted in the review: - Aspect ratio and uptake: cylindrical particles with aspect ratio 3 were internalized about 4-fold faster than aspect ratio 1 particles in HeLa cells,.
Read the article →Polymer Chemistry (Royal Society of Chemistry)2020ResearchDrug Delivery
Lu Sun, Hua Wei, Xiaoshuo Zhang, Chao Meng, Guiying Kang, Wei Ma, Liwei Ma, Baoyan Wang, Cuiyun Yu
Folic acid (FA)-mediated active targeting improves nanocarrier tumor specificity but exposes targeting ligands to the immune system, causing rapid clearance and nonspecific uptake. Existing acid-labile benzoic-imine PEG sheddable systems are insufficiently stable at physiological pH. A more stable, tumor-triggered sheddable PEG stealth is needed to protect FA in circulation and expose it at tumor sites while also promoting intracellular drug. P1 micelles: \(D_h\) = 41 nm, narrow size distribution; stable at pH 7.4. - pH-triggered destabilization: At pH 6.5, size increased from 41 nm to 80 nm after 24 h; at pH 5.0, size increased to 627 nm. -.
Read the article →Frontiers in Molecular Biosciences2020ReviewDrug Delivery
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A.
Conventional chemotherapy and targeted therapy are limited by systemic toxicity, poor tumor targeting, and multidrug resistance (MDR). Nanoparticle-based drug delivery offers improved pharmacokinetics, biocompatibility, enhanced permeability and retention (EPR), precise targeting, and potential to overcome resistance mechanisms such as efflux transporters, defective apoptosis, and hypoxia. NPs with diameters of 10–100 nm are generally suitable for cancer therapy; <10 nm are cleared by kidneys, >100 nm are cleared by phagocytes. - PEGylation reduces opsonization and immune clearance, prolonging.
Read the article →Journal of Oncology2020ReviewDrug Delivery
Zein R, Sharrouf W, Selting K.
Drug penetration into tumors is limited by abnormal vasculature and high interstitial pressure, and chemotherapy causes undesirable adverse effects including bone marrow and gastrointestinal toxicity. Nanotechnology-based drug delivery systems aim to reduce these adverse effects by enhancing penetration and selective drug retention in tumor tissues. A thorough knowledge of the physical properties (size, surface charge, shape, mechanical. 15 nm AuNPs showed highest accumulation in organs (liver, lung, spleen, kidney); only 15 and 50 nm AuNPs crossed the blood-brain barrier. - Renal clearance is rapid for particles <5–6 nm; clearance by liver and spleen.
Read the article →Journal of Controlled Release2016ResearchDrug Delivery
Cong Zhang, Tong An, Dan Wang, Guoyun Wan, Mingming Zhang, Hemei Wang, Sipei Zhang, Rongshan Li, Xiaoying Yang, Yinsong Wang
Hepatocellular carcinoma (HCC) has poor prognosis and limited effective systemic therapy. Combination antiangiogenesis and chemotherapy with paclitaxel (PTX) and combretastatin A4 (CA4) is synergistic, but both drugs have poor solubility, lack tumor targeting, and cause systemic toxicity. A tumor microenvironment–responsive carrier is needed to co-deliver them selectively to HCC. Nanoparticle properties: PBAE/PLGA nanoparticles were ~120 nm; CAPL/PBAE/PLGA nanoparticles were ~178.1 nm with zeta potential −17.8 mV and a core–shell structure with 20–50 nm shell. - pH-responsive charge reversal: At.
Read the article →International Journal of Nanomedicine2015ResearchNon-viral Gene Delivery
Zhenyu Shao, Jingyu Shao, Bingxu Tan, Shanghai Guan, Zhulong Liu, Zengjun Zhao, Fangfang He, Jian Zhao
Lung cancer chemotherapy is limited by multidrug resistance, severe adverse effects, and poor tumor targeting. A nanocarrier that actively targets lung cancer cells and co-delivers a cytotoxic drug plus therapeutic DNA could improve efficacy and reduce off-target toxicity. Tf₅ₖ-PTX-DNA-NLC: ~133 nm, zeta +19 mV; Tf₁₀ₖ-PTX-DNA-NLC: ~236 nm, zeta +8 mV. - DNA loading ~90–92%; PTX encapsulation ~83–87%. - In vitro IC₅₀: Tf₅ₖ-PTX-DNA-NLC 3.35 µM; Tf₁₀ₖ-PTX-DNA-NLC 7.12 µM; PTX-DNA-NLC 7.36.
Read the article →Journal of Controlled Release2007ResearchNon-viral Gene Delivery
Ayumi Sato, Sung Won Choi, Miwa Hirai, Asako Yamayoshi, Rui Moriyama, Takeshi Yamano, Motoki Takagi, Arihiro Kano, Akira Shimamoto, Atsushi Maruyama
Systemic siRNA therapeutics are limited by poor cell membrane permeability, rapid nuclease degradation, and renal clearance. A carrier with long circulatory half-life is needed for effective RNAi and potential tumor targeting via the enhanced permeation and retention (EPR) effect. Existing hydrophilic polymer-modified polyplexes can destabilize complexes, especially for oligonucleotides such as siRNA. Binding: CCC with higher side-chain content (28K5P90; 10 wt% PLL, 90 wt% PEG) showed stronger siRNA binding than lower side-chain content (28K5P70; 30 wt% PLL, 70 wt% PEG). - Stability: siRNA complexed with CCC was.
Read the article →